IRTC Stock Cash Flow Statements

iRhythm Technologies Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

iRhythm Technologies Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31

cash flows from operating activities
net income	-14,218,000	-30,700,000	-1,333,000	-46,182,000	-20,107,000	-45,667,000	-38,699,000	-27,116,000	-18,482,000	-39,109,000	-21,451,000	-23,897,000	-50,609,000	-32,491,000	-23,731,000	-17,360,000	-27,779,000	-9,651,000	-4,677,000	-20,437,000	-9,065,000	-17,300,000	-17,782,000	-11,467,000	-8,019,000	-14,713,000	-10,244,000	-12,206,000	-11,117,000	-11,149,000	-6,524,000	-6,444,000	-5,303,000	-6,266,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	5,105,000	5,210,000	5,289,000	5,135,000	5,160,000	5,131,000	4,914,000	4,067,000	3,791,000	3,576,000	3,436,000	3,351,000	3,143,000	3,104,000	2,549,000	2,153,000	2,036,000	1,978,000	1,702,000	1,669,000	1,551,000	1,188,000	965,000	671,000	621,000	596,000	568,000	557,000	548,000	494,000	468,000	337,000	298,000	-78,000
stock-based compensation	22,827,000	23,344,000	16,008,000	17,158,000	21,821,000	20,991,000	23,846,000	21,008,000	14,099,000	18,251,000	12,945,000	15,098,000	13,903,000	11,876,000	12,161,000	10,260,000	20,230,000	13,998,000	17,444,000	9,768,000	305,000	7,177,000	7,319,000	7,330,000	4,415,000	4,795,000	4,211,000	4,076,000	3,247,000	3,099,000	2,732,000	2,264,000	2,028,000	620,000
amortization of premium and accretion of discounts	-654,000	-619,000	-114,000	-87,000	-241,000	-908,000	-1,413,000	-1,416,000
amortization of operating lease right-of-use assets	1,423,000	1,393,000	1,315,000	1,263,000	1,240,000	1,244,000	1,553,000	1,494,000	1,384,000	1,365,000	-2,998,000	1,316,000	6,547,000		1,814,000	1,672,000	1,555,000		1,511,000	1,491,000	1,495,000		2,391,000	3,878,000	1,183,000
amortization of debt discount	770,000	794,000	623,000	843,000	752,000	578,000
change in fair value of strategic investments	-2,152,000	-843,000	-843,000
benefit from credit losses and contractual allowances	25,277,000	29,427,000	20,726,000	17,251,000
acquired in-process research and development	1,698,000	296,000	302,000
loss on extinguishment of debt			0	0	0	7,589,000
impairment charges			0								0	0	23,164,000
other	69,000	103,000	215,000	-179,000	290,000	106,000	703,000	-507,000	-35,000	176,000	3,000
changes in operating assets and liabilities:
accounts receivable	-26,791,000	-30,125,000	-23,240,000	-9,164,000	-14,998,000	-44,518,000	-29,389,000	-13,128,000	-17,612,000	-21,064,000	-17,683,000	-17,321,000	-22,878,000	-6,749,000	848,000	-7,853,000	-39,818,000	-11,957,000	-13,006,000	-3,005,000	-9,989,000	-5,930,000	-4,951,000	-6,860,000	-10,984,000	-7,797,000	-3,891,000	-5,661,000	-5,536,000	-4,390,000	-2,898,000	-2,314,000	-3,348,000	-1,400,000
inventory	-4,213,000	-388,000	817,000	425,000	-543,000	-923,000	-906,000	1,340,000	1,949,000	-1,404,000	-29,000	-1,969,000	-2,377,000	-317,000	-616,000	-2,419,000	-1,608,000	-330,000	-44,000	-824,000	-191,000	-538,000	-724,000	-270,000	-442,000	257,000	-152,000	-311,000	-174,000	-369,000	-83,000	-75,000	234,000	282,000
prepaid expenses and other current assets	2,624,000	-4,165,000	-2,860,000	1,687,000	-1,335,000	7,813,000	-9,487,000	-289,000	-207,000	-1,053,000	1,200,000	1,313,000	-146,000	-4,051,000	1,577,000	-242,000	387,000	-2,680,000	-939,000	478,000	114,000	-684,000	15,000	142,000	-169,000	-1,337,000	-277,000	-744,000	790,000	-598,000	-172,000	-428,000	403,000	-658,000
other assets	-446,000	729,000	3,835,000	4,392,000	-312,000	-4,694,000	-991,000	-8,325,000	-10,282,000	-3,189,000	-9,000	-1,032,000	-3,058,000	-1,358,000	-444,000	746,000	-775,000	-2,711,000	-710,000	-726,000	-2,002,000	-2,366,000	-1,192,000	-809,000	-365,000	-50,000	-306,000	216,000	409,000	326,000	-285,000	-162,000	-346,000	-393,000
accounts payable and accrued liabilities	15,171,000	-489,000	971,000	2,302,000	2,196,000	-12,877,000
deferred revenue	217,000	350,000	-99,000	-115,000	78,000	-238,000	-77,000	-312,000	209,000	435,000	27,000	43,000	-116,000	675,000	-133,000	1,082,000	495,000	-8,000	-259,000	82,000	-136,000	362,000	-289,000	-111,000	66,000	69,000	532,000	-457,000	-139,000	334,000	347,000	-423,000	33,000	97,000
operating lease liabilities	-1,527,000	-2,208,000	-2,380,000	-2,033,000	-1,358,000	-1,945,000	-1,797,000	-2,031,000	-1,702,000	-59,000	3,081,000	-1,598,000	-6,175,000	1,223,000	1,617,000	-1,212,000	-1,364,000	-1,284,000	-1,209,000	-1,163,000	-1,163,000	-1,162,000	-355,000	-2,524,000	-1,200,000
net cash from operating activities	27,659,000	-7,891,000	19,232,000	24,347,000	11,840,000	-52,029,000	-15,972,000	1,196,000	-4,572,000	-30,753,000	3,669,000	-372,000	-38,885,000	-13,045,000	17,677,000	-543,000	-41,842,000	7,818,000	10,942,000	-10,153,000	-22,366,000	-4,860,000	-222,000	318,000	-17,099,000	-4,348,000	-5,097,000	-6,363,000	-13,260,000	-3,723,000	-3,788,000	-1,001,000	-6,399,000	-1,034,000
capex	-10,369,000	-9,419,000	-6,844,000	-8,834,000	-8,488,000	-9,776,000	-13,517,000	-9,087,000	-9,397,000	-8,423,000	-6,333,000	-10,832,000	-5,572,000	-4,625,000	-13,308,000	-5,923,000	-4,211,000	-2,364,000	-5,601,000	-2,181,000	-3,405,000	-11,817,000	-4,172,000	-2,833,000	-1,635,000	-1,493,000	-1,461,000	-1,118,000	-1,108,000	-911,000	-531,000	-946,000	-1,174,000	-942,000
free cash flows	17,290,000	-17,310,000	12,388,000	15,513,000	3,352,000	-61,805,000	-29,489,000	-7,891,000	-13,969,000	-39,176,000	-2,664,000	-11,204,000	-44,457,000	-17,670,000	4,369,000	-6,466,000	-46,053,000	5,454,000	5,341,000	-12,334,000	-25,771,000	-16,677,000	-4,394,000	-2,515,000	-18,734,000	-5,841,000	-6,558,000	-7,481,000	-14,368,000	-4,634,000	-4,319,000	-1,947,000	-7,573,000	-1,976,000
cash flows from investing activities
purchases of property and equipment	-10,369,000	-9,419,000	-6,844,000	-8,834,000	-8,488,000	-9,776,000	-13,517,000	-9,087,000	-9,397,000	-8,423,000	-6,333,000	-10,832,000	-5,572,000	-4,625,000	-13,308,000	-5,923,000	-4,211,000	-2,364,000	-5,601,000	-2,181,000	-3,405,000	-11,817,000	-4,172,000	-2,833,000	-1,635,000	-1,493,000	-1,461,000	-1,118,000	-1,108,000	-911,000	-531,000	-946,000	-1,174,000	-942,000
purchases of marketable securities	-135,146,000	-34,320,000	-115,815,000	0	0	-2,426,000	-55,083,000	-36,351,000
maturities of marketable securities	44,600,000	5,600,000	2,500,000	8,500,000	38,000,000	52,200,000	70,000,000	30,000,000
purchases of strategic investments			-2,000,000	-40,000,000
net cash from investing activities	-100,915,000	-38,139,000	-122,159,000	-55,334,000	14,512,000	39,998,000	1,400,000	-15,438,000	9,009,000	3,820,000	-35,362,000	-431,000	-8,527,000	-27,133,000	13,660,000	1,702,000	117,035,000	-17,485,000	-204,481,000	29,664,000	59,911,000	-12,508,000	-87,872,000	-15,343,000	26,449,000	4,269,000	1,686,000	6,703,000	21,459,000	-10,472,000	6,233,000	-658,000	-29,696,000	-66,345,000
cash flows from financing activities
payment of svb term loan and termination costs			0	0	0	-37,751,000
proceeds from braidwell debt			0	0	0	75,000,000
payments of issuance costs for braidwell debt			0	0	-297,000	-1,803,000
payment of braidwell debt and termination costs			0	0	0	-78,660,000
proceeds from issuance of 2029 notes			0	0	0	661,250,000
payments of issuance costs for 2029 notes			0	-183,000	-649,000	-16,592,000
purchases of capped call transactions			0	0	0	-72,407,000
purchase of treasury stock			0	0	0	-25,000,000
proceeds from issuance of common stock in connection with employee equity incentive plans	7,094,000	1,729,000	2,987,000	148,000	4,734,000	604,000	3,468,000	66,000	4,381,000	905,000	1,662,000	7,296,000	1,076,000	3,286,000	80,000	4,001,000	1,576,000	6,562,000
net cash from financing activities	7,094,000	1,729,000	2,987,000	-35,000	3,788,000	504,641,000	3,468,000	66,000	4,381,000	905,000	1,662,000	7,270,000	14,636,000	369,000	-2,838,000	338,000	-26,446,000	2,959,000	207,145,000	5,705,000	-1,493,000	3,196,000	106,574,000	2,944,000	-1,138,000	2,757,000	1,515,000	2,428,000	-397,000	2,437,000	1,735,000	2,325,000	35,000	113,261,000
effect of exchange rate changes	-11,000	-18,000					-201,000	76,000
net increase in cash, cash equivalents and restricted cash	-66,173,000	-44,319,000
cash, cash equivalents and restricted cash, beginning of period	0	427,955,000
cash, cash equivalents and restricted cash, end of period	-66,173,000	383,636,000
sales of marketable securities
purchase of acquired in-process research and development
proceeds from svb term loan
net increase in cash and cash equivalents											-30,031,000	6,467,000	-32,776,000	-39,809,000	28,499,000	1,497,000	48,747,000	-6,708,000	13,606,000	25,216,000	36,052,000	-14,172,000				2,678,000	-1,896,000	2,768,000	7,802,000
cash and cash equivalents, beginning of year
cash and cash equivalents, end of year
purchases of acquired in-process research and development
effect of exchange rate changes on cash				5,000	-9,000	-4,000
net increase in cash, cash equivalents, and restricted cash				-31,017,000	30,131,000	492,606,000																		-12,081,000	8,212,000
cash, cash equivalents, and restricted cash, beginning of period				0	0	36,173,000
cash, cash equivalents, and restricted cash, end of period				-31,017,000	30,131,000	528,779,000
supplemental disclosures of cash flow information:
interest paid					0	1,595,000	774,000	769,000	739,000	678,000	462,000	247,000	1,967,000	251,000	285,000	327,000	331,000	370,000	336,000	402,000	394,000	398,000	410,000	425,000	411,000	3,513,000	804,000	961,000	787,000	398,000	777,000	0	375,000	378,000
cash taxes paid					349,000	11,000	336,000	506,000	280,000	8,000
cash received from tenant improvement allowances							0	0	0	1,603,000
non-cash investing and financing activities:
property and equipment costs included in accounts payable and accrued liabilities					210,000	23,000				203,000			225,000		-5,283,000	5,204,000	115,000		-1,322,000	1,233,000	136,000
capitalized stock-based compensation in property and equipment					2,180,000	1,649,000	1,787,000	1,820,000
benefit from doubtful accounts and contractual allowances						16,289,000	17,973,000	14,169,000	16,061,000	21,425,000	14,529,000	15,227,000	14,022,000		9,755,000	4,412,000	9,768,000		6,927,000	4,340,000	9,184,000		6,898,000	5,974,000	4,709,000		2,481,000	3,760,000	2,680,000
accounts payable							-1,668,000	62,000	-2,629,000	2,262,000	1,417,000	786,000	-5,308,000	5,643,000	-1,381,000	1,200,000	673,000	819,000	-160,000	-1,705,000	-2,835,000	5,723,000	-1,144,000	1,358,000	-333,000	332,000	-630,000	1,056,000	-950,000	667,000	-559,000	1,216,000	-690,000	236,000
accrued liabilities							8,388,000	12,180,000	9,958,000	-11,228,000	9,348,000	8,153,000	-9,429,000	-3,392,000	13,323,000	4,155,000	-6,140,000	6,673,000	4,324,000	-222,000	-9,467,000	367,000	8,822,000	3,193,000	-6,380,000	7,441,000	2,838,000	3,474,000	-2,977,000	4,070,000	1,075,000	2,092,000	-1,873,000	3,743,000
purchase of strategic investment							0	0
payment of loans
proceeds from term loans
tax withholding upon vesting of restricted stock awards														0	-1,000	-747,000	-25,105,000	-1,297,000	-3,563,000	-687,000	-4,462,000	-177,000	-1,554,000	-299,000	-3,258,000	-2,239,000	-100,000	-264,000	-1,274,000
payment of issuance costs for long-term debt
right-of-use assets obtained in exchange for operating lease liabilities							-117,000				0	0	7,666,000
proceeds from term loan											0	0	35,000,000
payments of issuance costs for long-term debt
net decrease in cash and cash equivalents								-14,100,000	8,774,000	-26,028,000																					4,180,000	666,000	-36,060,000
cash and cash equivalents, beginning of period								0	0	78,832,000																					0	0	51,643,000
cash and cash equivalents, end of period								-14,100,000	8,774,000	52,804,000																					4,180,000	666,000	15,583,000
property and equipment included in accounts payable and accrued liabilities								-18,000
amortization of premium and accretion of discounts on investments										-1,137,000
purchases of short-term investments										-33,757,000
sales of short-term investments
maturities of short-term investments										46,000,000
capitalized stock-based compensation										1,648,000	1,524,000	1,532,000	1,250,000	1,059,000	902,000	721,000	911,000
accretion of discounts on investments											-147,000													-192,000	-227,000
reimbursement of tenant improvement allowance															0
payment of long-term debt											0	0	-21,389,000
payments of issuance costs for long term debt											0	-26,000	-51,000
cash and cash equivalents beginning of period											0	0	127,562,000		0	0	88,628,000		0	0	20,462,000
cash and cash equivalents end of period											-30,031,000	6,467,000	94,786,000		28,499,000	1,497,000	137,375,000		13,606,000	25,216,000	56,514,000
supplemental disclosures of cash flow information
non-cash investing and financing activities
purchases of available-for-sale investments												-45,545,000	-45,974,000	-55,508,000	-20,247,000	-16,375,000	-30,054,000	-62,621,000	-206,880,000	0	-8,009,000	-19,889,000	-101,050,000	-35,360,000	-9,616,000	-19,088,000	-31,454,000	-37,179,000	-5,437,000	-39,586,000	-34,209,000	-24,212,000	-31,822,000
sales of available-for-sale investments												19,946,000	15,019,000					0	0	0	14,525,000
maturities of available-for-sale investments												36,000,000	28,000,000	33,000,000	47,215,000	24,000,000	151,300,000	47,500,000	8,000,000	31,845,000	56,800,000	17,700,000	17,350,000	22,850,000	37,700,000	18,888,000	34,601,000	45,000,000	28,004,000	30,025,000	40,882,000	24,500,000	3,300,000
accretion of discounts on investments, net and other													432,000		338,000	512,000	498,000		38,000
amortization of debt discount and issuance costs																					4,000	4,000	2,000	5,000	26,000	92,000	-7,000	61,000	64,000	63,000	69,000	64,000	64,000	-33,000
accretion of discounts on investments, net of premium amortization																					-171,000	-268,000
benefit from bad debt and contractual allowance																														3,476,000	1,711,000
cost of operating lease right-of-use assets
issuance of common stock in connection with follow-on public offering
repayments of long-term debt
deferred offering costs included in accounts payable and accrued liabilities
right-of-use assets obtained in exchange for new operating lease liabilities																290,000	5,757,000	0	0	0	621,000	-310,000
issuance of common stock in follow-on public offering, net of offering costs
offering costs included in accounts payable and accrued liabilities
payment of long term debt																-2,916,000	-2,917,000
loss on disposal of assets																										4,000
repayment of interest paid in kind
deferred rent																										52,000	-8,000	-5,000	66,000	-8,000	29,000			-1,000
proceeds from long-term debt, net of debt discount
premiums paid on extinguishment of debt
issuance of common stock in connection with follow-on public offering, net of offering costs
offering costs in accounts payable and accrued liabilities
proceeds from issuance of common stock																				6,392,000	2,969,000	3,086,000	1,000,000	3,289,000	2,120,000		1,615,000	4,192,000	877,000
non-cash interest expense																														398,000	393,000	384,000	375,000	382,000
payments of deferred offering costs
issuance of common stock in public offering
repayment of debt																											0
stock offering costs included in accounts payable and accrued liabilities
cash, cash equivalents and restricted cash beginning of period																								0	20,023,000		0	0	8,671,000
cash, cash equivalents and restricted cash end of period																								-12,081,000	28,235,000		-1,896,000	2,768,000	16,473,000
property, plant and equipment costs included in liabilities
property, plant and equipment costs included in accounts payable and accrued liabilities																									38,000		-132,000
amortization (accretion) on investments
change in fair value of preferred stock warrant liabilities																																		1,127,000
proceeds from issuance of common stock upon exercise of stock options, net of repurchases																																	35,000	50,000
proceeds from issuance of common stock upon exercise of warrants
proceeds from long-term debt, net of debt discount and issuance costs
proceeds of issuance of common stock upon initial public offering
conversion of preferred stock to common stock
conversion of preferred stock warrants to common stock warrants
amortization of premiums (accretion of discounts) on investments																											-283,000	-179,000	-171,000		-91,000	-70,000	-46,000
property, plant and equipment costs included in accounts payable																													80,000		-22,000
change in accrued interest
restricted cash
proceeds from issuance of convertible preferred stock, net of issuance costs
payments of issuance costs for revolving line of credit
issuance of warrants to purchase preferred stock
series e convertible preferred stock issuance costs included in accrued liabilities
property and equipment included in accounts payable																																		271,000
change in restricted cash
net proceeds from employee stock transactions
payments of deferred issuance costs
proceeds from issuance of common stock related to the exercise of options and employee stock purchase program, net of repurchases
change in allowance for doubtful accounts and contractual allowance																																	1,772,000
series e preferred stock issuance costs included in accrued liabilities
deferred offering costs included in accounts payables and accrued liabilities

We provide you with 20 years of cash flow statements for iRhythm Technologies stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of iRhythm Technologies stock. Explore the full financial landscape of iRhythm Technologies stock with our expertly curated income statements.

The information provided in this report about iRhythm Technologies stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.